37571 |
Immunology |
Immunological Characteristics of Hyperprogressive Disease in Patients ... |
IMMUNE NETW 2020 10.4110/in.2020.20.e48 |
이세훈 |
2020 |
37570 |
Pharmacology & Pharmacy |
Evaluating entrectinib as a treatment option for non-small cell lung c... |
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 |
이세훈 |
2020 |
37569 |
Oncology |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell L... |
CANCER RES TREAT 2020 10.4143/crt.2020.278 |
이세훈 |
2020 |
37568 |
Multidisciplinary Sciences |
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immuni... |
ISCIENCE 2020 10.1016/j.isci.2020.101386 |
이세훈 |
2020 |
37567 |
Oncology |
Clinical outcomes of immune checkpoint inhibitors for patients with re... |
BMC CANCER 2020 10.1186/s12885-020-07214-4 |
이세훈 |
2020 |
37566 |
Respiratory System |
Are there any ethnic differences in the efficacy and safety of immune ... |
J THORAC DIS 2020 10.21037/jtd.2019.08.29 |
이세훈 |
2020 |
37565 |
Oncology |
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGF... |
ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 |
이세훈 |
2020 |
37564 |
Cardiac & Cardiovascular Systems; Respiratory System; Surgery |
Utility of positron emission-computed tomography for predicting pathol... |
EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181 |
선종무 |
2020 |
37563 |
Oncology; Respiratory System |
The different central nervous system efficacy among gefitinib, erlotin... |
TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 |
선종무 |
2020 |
37562 |
Oncology; Immunology |
Nivolumab for esophageal squamous cell carcinoma and the predictive ro... |
CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02766-7 |
선종무 |
2020 |